SCHEMBL1934464

SCHEMBL1934464

N#CC1C=CC(O)=CC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2697903 0.70
SCHEMBL1745971 0.70
SCHEMBL16418366 0.68
SCHEMBL10452168 0.68
SCHEMBL17372870 0.65
SCHEMBL5095651 0.63
SCHEMBL2361865 0.59
SCHEMBL11203576 0.58
SCHEMBL28275764 0.56
SCHEMBL10706676 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020028593-A1 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) Oncternal Therapeutics, Inc. (US) 2020-02-06 WO disclosed
EP-2509602-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-10-17 EP disclosed
WO-2011068667-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed